{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16","upperLimit":"62","value":"37"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Disease control rate is defined as N (%) patients with CR, PR, or SD by 24 weeks on study using RECIST version 1.1. For SD determination for DCR, the patient must have lack of progression for the first 24 weeks on study. Disease control rate will be assessed in the Response-evaluable and As-treated populations. Will be evaluated by RECIST version 1.1. Will be estimated with 95% confidence interval.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received 7 mg of MEDI0457 intramuscularly (weeks 1, 3, 7, 12, and every 8 weeks thereafter) and durvalumab 1500 mg intravenously every 4 weeks starting at week 4.","id":"OG000","title":"Treatment Group"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Disease Control Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}